Panbela Therapeutics Releases Promising Data on CPP-1X in Recent Onset Type 1 Diabetes
Panbela Therapeutics, a clinical stage biopharmaceutical company at the forefront of developing disruptive therapeutics for patients facing urgent unmet medical needs, has unveiled groundbreaking preclinical